Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

2',3'-cGAMP

2',3'-cGAMP (2'-3'-cyclic GMP-AMP) is a endogenous cGAMP in mammalian cells. 2',3'-cGAMP binds to STING with a high affinity and is a potent inducer of interferon-β (IFNβ) . 2',3'-cGAMP is produced in mammalian cells in response to DNA in the cytoplasm[1].

Product Specifications

CAS Number

[1441190-66-4]

Product Name Alternative

2'-3'-cyclic GMP-AMP

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Endogenous Metabolite; IFNAR; STING

Type

Reference compound

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/2-3-cgamp.html

Purity

99.95

Solubility

H2O : ≥ 50 mg/mL

Smiles

OC1([H])[C@](OP(O)(OC[C@](O[C@@H](N2C3=NC=NC(N)=C3N=C2)[C@@H]4O)([H])[C@@]4([H])O5)=O)([H])[C@H](N6C(NC(N)=NC7=O)=C7N=C6)O[C@]1([H])COP5(O)=O

Molecular Formula

C20H24N10O13P2

Molecular Weight

674.41

Precautions

H302, H315, H319

References & Citations

[1]Zhang X, et al. Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. Mol Cell. 2013 Jul 25;51 (2) :226-35.

Shipping Conditions

Blue Ice

Storage Conditions

-20°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Citation 01

ACS Appl Bio Mater. 2024 Oct 21;7 (10) :6768-6779.|Acta Materia Medica . 2023 Jun 17.|Adv Sci (Weinh) . 2024 Dec 11:e2408323.|Bioact Mater. 2024 Sep 6:42:345-365.|Brain Behav Immun. 2026 Jan:131:106176.|Cell Commun Signal. 2023 Sep 28;21 (1) :264.|Genes Dis. 2025 Aug 14.|J Immunol. 2021 Apr 15;206 (8) :1844-1857.|J Virol. 2023 Nov 30;97 (11) :e0127923.|Mol Pain. 2025 May 7:17448069251342240.|Nat Commun. 2025 Jun 3;16 (1) :5140.|Res Sq. 2024 May 30.|SSRN. 2025 Jan 24.|World J Tradit Chin Med. 2025 Oct 28.|ACS Nano. 2025 Feb 25;19 (7) :6758-6770.|Adv Mater. 2024 Mar 24:e2401384.|Adv Sci (Weinh) . 2024 Nov 19:e2407222.|bioRxiv. 2024 Apr 12.|bioRxiv. 2025 Nov 17.|Cancers (Basel) . 2024 Oct 30;16 (21) :3657.|Cell Rep. 2023 Feb 28;42 (3) :112145.|Fundam Res. 2023 May 11;5 (1) :183-191.|Hum Vaccin Immunother. 2025 Dec;21 (1) :2567703.|J Med Chem. 2025 Mar 13;68 (5) :5471-5487.|Neuron. 2023 Jan 18;111 (2) :236-255.e7.|Neuropharmacology. 2025 Mar 19:110426.|Protein Cell. 2022 Apr;13 (4) :281-301.

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

Human Monoclonal EGFR Antibody (zalutumumab) [Janelia Fluor 525]

NBP3-28495JF525 0.1 mL

Human Monoclonal EGFR Antibody (zalutumumab) [Janelia Fluor 525]

Ask

Rabbit anti-human Phospholipase A2, membrane associated polyclonal Antibody, Biotin conjugated

MBS719648-01 0.05 mg

Rabbit anti-human Phospholipase A2, membrane associated polyclonal Antibody, Biotin conjugated

Ask

Rabbit anti-human Phospholipase A2, membrane associated polyclonal Antibody, Biotin conjugated

MBS719648-02 0.1 mg

Rabbit anti-human Phospholipase A2, membrane associated polyclonal Antibody, Biotin conjugated

Ask

Rabbit anti-human Phospholipase A2, membrane associated polyclonal Antibody, Biotin conjugated

MBS719648-03 5x 0.1 mg

Rabbit anti-human Phospholipase A2, membrane associated polyclonal Antibody, Biotin conjugated

Ask

Bucinnazine hydrochloride (controlled substance)

RM-B031400-01 10 mg

Bucinnazine hydrochloride (controlled substance)

Ask

Bucinnazine hydrochloride (controlled substance)

RM-B031400-02 25 mg

Bucinnazine hydrochloride (controlled substance)

Ask